LC3 ‐associated phagocytosis and human diseases: Insights from mechanisms to therapeutic potential
The FASEB Journal · 31.10.2024 · 38 (20)
DOI: 10.1096/fj.202402126r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 24.10.2024. Verfasst von Xu Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Phagocytosis, Microtubule-Associated Proteins. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Shaanxi Provincial Postdoctoral Science Foundation.
Abstract (Originalsprache)
LC3‐associated phagocytosis (LAP) is a distinct type of autophagy that involves the sequestration of extracellular material by phagocytes. Beyond the removal of dead cells and cellular debris from eukaryotic cells, LAP is also involved in the removal of a variety of pathogens, including bacteria, fungi, and viruses. These events are integral to multiple physiological and pathological processes, such as host defense, inflammation, and tissue homeostasis. Dysregulation of LAP has been associated with the pathogenesis of several human diseases, including infectious diseases, autoimmune diseases, and neurodegenerative diseases. Thus, understanding the molecular mechanisms underlying LAP and its involvement in human diseases may provide new insights into the development of novel therapeutic strategies for these conditions. In this review, we summarize and highlight the current consensus on the role of LAP and its biological functions in disease progression to propose new therapeutic strategies. Further studies are needed to illustrate the precise role of LAP in human disease and to determine new therapeutic targets for LAP‐associated pathologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.
- State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, China.
ORCID-Profile: Xu Chen, Qi Su, Ruize Gong, Xing Ling, Runxiao Xu, Qijia Feng, Jialiang Ke, Meng Liu, Gulipiyanmu Kahaerjiang, Yuhang Liu, Yanyan Yang, Zhihong Jiang, Hongmei Wu, Yitao Qi
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Shaanxi Provincial Postdoctoral Science Foundation
- Excellent Graduate Training Program of Shaanxi Normal University
- Macao Youth Scholars Program
Zitieren
APA
Chen, X., Su, Q., Gong, R., Ling, X., Xu, R., Feng, Q., Ke, J., Liu, M., Kahaerjiang, G., Liu, Y., Yang, Y., Jiang, Z., Wu, H., & Qi, Y. (2024). LC3 ‐associated phagocytosis and human diseases: Insights from mechanisms to therapeutic potential. The FASEB Journal, 38(20). https://doi.org/10.1096/fj.202402126r
Vancouver
Chen X, Su Q, Gong R, Ling X, Xu R, Feng Q, et al. LC3 ‐associated phagocytosis and human diseases: Insights from mechanisms to therapeutic potential. The FASEB Journal. 2024;38(20). doi:10.1096/fj.202402126r
BibTeX
@article{Chen2024,
author = {Chen, Xu and Su, Qi and Gong, Ruize and Ling, Xing and Xu, Runxiao and Feng, Qijia and Ke, Jialiang and Liu, Meng and Kahaerjiang, Gulipiyanmu and Liu, Yuhang and Yang, Yanyan and Jiang, Zhihong and Wu, Hongmei and Qi, Yitao},
title = {LC3 ‐associated phagocytosis and human diseases: Insights from mechanisms to therapeutic potential},
journal = {The FASEB Journal},
year = {2024},
volume = {38},
number = {20},
doi = {10.1096/fj.202402126r}
}
EUVIMED